查看购物车
  • Traditional Chinese
  • English
2021-2031年欧洲抗生素和抗真菌药物市场报告：范围、细分、动态和竞争分析
市场调查报告书
商品编码
1871448

2021-2031年欧洲抗生素和抗真菌药物市场报告：范围、细分、动态和竞争分析

Europe Antibiotics & Antimycotics Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 197 Pages | 订单完成后即时交付

价格

欧洲抗生素和抗真菌药物市场预计将大幅成长，到 2031 年将达到约 198.7 亿美元，高于 2023 年的 134.8 亿美元，预测期内年复合成长率(CAGR) 为 5.0%。

执行摘要和市场分析

市场分为多个区域，包括英国、德国、法国、义大利、西班牙和欧洲其他地区。市场成长的主要驱动力是细菌和真菌感染发生率的上升，以及各国政府为促进合理使用抗生素和抗真菌药物而采取的措施。此外，产品发布、监管审批和主要产业参与者之间的合作等策略措施预计也将进一步刺激欧洲市场成长。

市场区隔

欧洲抗生素和抗真菌药物市场分析按药物类别、适应症、给药途径和配销通路进行分类：

  • 药物类别：市场涵盖多种药物类别，例如青霉素类、头孢菌素类、碳青霉烯类、大环内酯类、氨基糖苷类、喹诺酮类、磺胺类、四环素类、唑类等。 2023年，青霉素类占据最大的市占率。
  • 适应症：市场细分为皮肤感染、呼吸道感染、泌尿道感染、败血症、耳部感染、胃肠道感染及其他感染。 2023年，呼吸道感染占最大市场份额。
  • 给药途径：包括口服、外用及其他方法，其中口服给药在 2023 年最为常见。
  • 配销通路：市场分为医院药房、零售药房和线上药房，其中医院药房在 2023 年的市场份额领先。

市场展望

抗生素和抗真菌药物行业的公司正积极致力于开发新产品和改进现有产品，并获得了药物研发和临床试验的资金支持。近期市场发展动态包括：

  • 2024 年 9 月，总部位于英国的生物製药公司 F2G 获得了 1 亿美元的资金，用于推进 olorofim 的后期开发。 olorofim 是一种新型口服抗真菌药物，用于治疗侵袭性曲菌病和其他真菌感染。
  • 2024 年 6 月，全球抗生素研发合作组织 (GARDP) 与 Bugworks Research Inc. 合作开发了 BWC0977，这是一种针对多重抗药性细菌的广谱抗生素。
  • 2023 年 6 月，BioVersys 成为第一家获得 AMR 行动基金资助的欧洲公司，用于开展旨在对抗细菌抗药性的临床试验，并计划在 2030 年前推出 2-4 种新的抗菌药物。
  • 2022 年 10 月，CARB-X 启动了几轮以关键健康需求为重点的融资，包括治疗新生儿败血症和淋病的疗法，以解决紧迫的抗菌素抗药性问题。

这些持续的资金投入和研究计画有望在未来几年为抗生素和抗真菌药物市场创造巨大的成长机会。

国家概况

按国家/地区分類的市场分析显示，德国在2023年占据最大市场份额。德国的成长归因于细菌和真菌感染的高发生率以及人们对抗菌素抗药性（AMR）认识的提高。报告显示，德国每年有超过50万人罹患肺炎，其中相当一部分人需要住院治疗。此外，罗伯特·科赫研究所报告称，每年有40万至60万名患者发生医院感染，造成数千人死亡。

德国政府已实施多项措施以促进抗生素的可持续使用，其中包括旨在优化处方行为的《德国抗生素抗药性策略》（DART 2030）。市场参与者之间的合作，例如勃林格殷格翰、Evotec 和 bioMerieux 于 2022 年 6 月成立的合资企业 Aurobac，预计也将促进市场成长。

公司简介

抗生素和抗真菌药物市场的主要参与者包括辉瑞公司、诺华公司、赛诺菲公司、罗氏公司、默克公司、葛兰素史克公司、强生公司、西普拉公司、拜耳公司、艾伯维公司和安斯泰来製药公司。这些公司正在推行各种策略，包括扩张、产品创新以及併购，以增强其市场份额并为消费者提供创新解决方案。

目录

第一章：引言

第二章：执行概要

  • 关键见解

第三章：研究方法

  • 二手研究
  • 初步研究
    • 假设的提出：
    • 宏观经济因素分析：
    • 发展基础数字：
    • 数据三角测量：
    • 国家层面资料：

第四章：欧洲抗生素和抗真菌药物市场－主要市场动态

  • 市场驱动因素
    • 传染病发生率不断上升
    • 人们对真菌感染的认识不断提高
  • 市场限制
    • 抗菌素抗药性、经济障碍和繁琐的监管程序
  • 市场机会
    • 持续的资金投入与研发计划
  • 未来趋势
    • 产品开发和治疗输送方法的技术进步
  • 驾驶员和安全带的影响：

第五章：抗生素和抗真菌药物市场——欧洲分析

  • 2021-2031年欧洲抗生素和抗真菌药物市场收入
  • 欧洲抗生素和抗真菌药物市场预测分析

第六章：欧洲抗生素与抗霉菌药物市场分析－依药物类别划分

  • 青霉素
  • 头孢菌素
  • 碳青霉烯类
  • 大环内酯类
  • 氨基糖苷类
  • 奎诺酮类
  • 磺胺类药物
  • 四环素类
  • 唑类
  • 其他的

第七章：欧洲抗生素与抗霉菌药物市场分析－依适应症划分

  • 皮肤感染
  • 呼吸道感染
  • 泌尿道感染（UTI）
  • 败血症
  • 耳部感染
  • 胃肠道感染
  • 其他的

第八章：欧洲抗生素和抗真菌药物市场分析－按给药途径划分

  • 口服
  • 主题
  • 其他的

第九章：欧洲抗生素和抗真菌药物市场分析－按配销通路划分

  • 医院药房
  • 零售药局
  • 网路药局

第十章：欧洲抗生素和抗真菌药物市场——国别分析

  • 欧洲
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 英国
    • 欧洲其他地区

第十一章：抗生素和抗真菌药物市场——产业概况

  • 概述
  • 抗生素和抗真菌药物市场成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第十二章：公司简介

  • Pfizer Inc
  • Novartis AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • GSK Plc
  • Johnson & Johnson
  • Cipla Ltd
  • Bayer AG
  • AbbVie Inc
  • Astellas Pharma Inc

第十三章：附录

Product Code: BMIRE00032105

The European antibiotics and antimycotics market is projected to grow significantly, reaching approximately USD 19.87 billion by 2031, up from USD 13.48 billion in 2023, reflecting a compound annual growth rate (CAGR) of 5.0% during the forecast period.

Executive Summary and Market Analysis

The market is divided into several regions, including the UK, Germany, France, Italy, Spain, and the Rest of Europe. The growth of this market is primarily driven by the rising incidence of bacterial and fungal infections, alongside increasing government initiatives aimed at promoting the responsible use of antibiotics and antimycotics. Additionally, strategic actions such as product launches, regulatory approvals, and collaborations among key industry players are expected to further stimulate market growth in Europe.

Market Segmentation

The analysis of the European antibiotics and antimycotics market is categorized based on drug class, indication, route of administration, and distribution channel:

  • Drug Class: The market includes various drug classes such as penicillins, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, penicillins held the largest market share.
  • Indication: The market is segmented into skin infections, respiratory infections, urinary tract infections (UTIs), septicemia, ear infections, gastrointestinal infections, and others. Respiratory infections accounted for the largest share in 2023.
  • Route of Administration: This includes oral, topical, and other methods, with oral administration being the most prevalent in 2023.
  • Distribution Channel: The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies leading in market share in 2023.

Market Outlook

Companies in the antibiotics and antimycotics sector are actively engaged in developing new products and enhancing existing ones, supported by funding for drug development and clinical trials. Recent developments in the market include:

  • In September 2024, F2G, a UK-based biopharmaceutical firm, secured USD 100 million to advance the late-stage development of olorofim, a novel oral antifungal treatment for invasive aspergillosis and other fungal infections.
  • In June 2024, the Global Antibiotic Research & Development Partnership (GARDP) collaborated with Bugworks Research Inc. to develop BWC0977, a broad-spectrum antibiotic targeting multidrug-resistant bacteria.
  • In June 2023, BioVersys became the first European company to receive funding from the AMR Action Fund for clinical trials aimed at combating bacterial resistance, with plans to launch 2-4 new antimicrobials by 2030.
  • In October 2022, CARB-X initiated funding rounds focused on critical health needs, including therapeutics for neonatal sepsis and gonorrhea, addressing urgent antimicrobial resistance issues.

These ongoing funding and research initiatives are expected to create significant growth opportunities in the antibiotics and antimycotics market in the coming years.

Country Insights

The market analysis by country reveals that Germany held the largest share in 2023. The growth in Germany is attributed to the high prevalence of bacterial and fungal infections and increased awareness of antimicrobial resistance (AMR). Reports indicate that over 500,000 individuals in Germany are affected by pneumonia annually, with a substantial number requiring hospitalization. Furthermore, the Robert Koch Institute reported that 400,000 to 600,000 patients experience hospital-acquired infections each year, leading to thousands of deaths.

The German government has implemented various initiatives to promote sustainable antibiotic use, including the German Antibiotic Resistance Strategy (DART 2030), which focuses on optimizing prescribing practices. Collaborative efforts among market players, such as the joint venture Aurobac launched by Boehringer Ingelheim, Evotec, and bioMerieux in June 2022, are also expected to enhance market growth.

Company Profiles

Key players in the antibiotics and antimycotics market include Pfizer Inc., Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc., and Astellas Pharma Inc. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Europe Antibiotics and Antimycotics Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increasing Prevalence of Infectious Diseases
    • 4.1.2 Growing Awareness About Fungal Infections
  • 4.2 Market Restraints
    • 4.2.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
  • 4.3 Market Opportunities
    • 4.3.1 Ongoing Funding and Research & Development Initiatives
  • 4.4 Future Trends
    • 4.4.1 Technological Advancements in Product Development and Treatment Delivery Approaches
  • 4.5 Impact of Drivers and Restraints:

5. Antibiotics and Antimycotics Market - Europe Analysis

  • 5.1 Europe Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • 5.2 Europe Antibiotics and Antimycotics Market Forecast Analysis

6. Europe Antibiotics and Antimycotics Market Analysis - by Drug Class

  • 6.1 Penicillin
    • 6.1.1 Overview
    • 6.1.2 Penicillin: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.2 Cephalosporines
    • 6.2.1 Overview
    • 6.2.2 Cephalosporines: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.3 Carbapenems
    • 6.3.1 Overview
    • 6.3.2 Carbapenems: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.4 Macrolides
    • 6.4.1 Overview
    • 6.4.2 Macrolides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.5 Aminoglycosides
    • 6.5.1 Overview
    • 6.5.2 Aminoglycosides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.6 Quinolones
    • 6.6.1 Overview
    • 6.6.2 Quinolones: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.7 Sulfonamides
    • 6.7.1 Overview
    • 6.7.2 Sulfonamides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.8 Tetracyclines
    • 6.8.1 Overview
    • 6.8.2 Tetracyclines: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.9 Azoles
    • 6.9.1 Overview
    • 6.9.2 Azoles: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.10 Others
    • 6.10.1 Overview
    • 6.10.2 Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Europe Antibiotics and Antimycotics Market Analysis - by Indication

  • 7.1 Skin Infections
    • 7.1.1 Overview
    • 7.1.2 Skin Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Respiratory Infections
    • 7.2.1 Overview
    • 7.2.2 Respiratory Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Urinary Tract Infections (UTI)
    • 7.3.1 Overview
    • 7.3.2 Urinary Tract Infections (UTI): Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Septicemia
    • 7.4.1 Overview
    • 7.4.2 Septicemia: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.5 Ear Infections
    • 7.5.1 Overview
    • 7.5.2 Ear Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.6 Gastrointestinal Infections
    • 7.6.1 Overview
    • 7.6.2 Gastrointestinal Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Antibiotics and Antimycotics Market Analysis - by Route Of Administration

  • 8.1 Oral
    • 8.1.1 Overview
    • 8.1.2 Oral: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Topical
    • 8.2.1 Overview
    • 8.2.2 Topical: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Antibiotics and Antimycotics Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Online Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Online Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Antibiotics and Antimycotics Market - Country Analysis

  • 10.1 Europe
    • 10.1.1 Europe Antibiotics and Antimycotics Market Overview
    • 10.1.2 Europe Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 10.1.2.1 Europe Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 10.1.2.2 Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.2.1 Germany: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.2.2 Germany: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.2.3 Germany: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.2.4 Germany: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 10.1.2.3 France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.3.1 France: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.3.2 France: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.3.3 France: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.3.4 France: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 10.1.2.4 Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.4.1 Spain: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.4.2 Spain: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.4.3 Spain: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.4.4 Spain: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 10.1.2.5 Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.5.1 Italy: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.5.2 Italy: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.5.3 Italy: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.5.4 Italy: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 10.1.2.6 United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.6.1 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.6.2 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.6.3 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.6.4 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 10.1.2.7 Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.7.1 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.7.2 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.7.3 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.7.4 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel

11. Antibiotics and Antimycotics Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Antibiotics and Antimycotics Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Novartis AG
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Sanofi SA
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 F. Hoffmann-La Roche Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Merck & Co Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 GSK Plc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Johnson & Johnson
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Cipla Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Bayer AG
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 AbbVie Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Astellas Pharma Inc
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Antibiotics and Antimycotics Market Segmentation
  • Table 2. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Drug Class
  • Table 4. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indication
  • Table 5. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Route Of Administration
  • Table 6. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 7. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 9. Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 10. Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 11. Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 12. France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 13. France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 14. France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 15. France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 16. Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 17. Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 18. Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 19. Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 20. Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 21. Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 22. Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 23. Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 24. United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 25. United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 26. United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 27. United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 28. Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 29. Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 30. Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 31. Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 32. Recent Organic Growth Strategies in Antibiotics and Antimycotics Market
  • Table 33. Recent Inorganic Growth Strategies in the Antibiotics and Antimycotics Market
  • Table 34. Glossary of Terms, Antibiotics and Antimycotics Market

List Of Figures

  • Figure 1. Europe Antibiotics and Antimycotics Market Segmentation - Country
  • Figure 2. Europe Antibiotics and Antimycotics Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Europe Antibiotics and Antimycotics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 6. Penicillin: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Cephalosporines: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Carbapenems: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Macrolides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Aminoglycosides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Quinolones: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 12. Sulfonamides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Tetracyclines: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Azoles: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Europe Antibiotics and Antimycotics Market Share (%) - by Indication (2023 and 2031)
  • Figure 17. Skin Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Respiratory Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Urinary Tract Infections (UTI): Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Septicemia: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Ear Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Gastrointestinal Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 23. Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. Europe Antibiotics and Antimycotics Market Share (%) - by Route Of Administration (2023 and 2031)
  • Figure 25. Oral: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 26. Topical: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 27. Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 28. Europe Antibiotics and Antimycotics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 29. Hospital Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 30. Retail Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 31. Online Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 32. Europe Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 33. Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 34. France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 35. Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 36. Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 37. United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 38. Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 39. Growth Strategies in Antibiotics and Antimycotics Market